Accuray Incorporated Company Profile (NASDAQ:ARAY)

Accuray Incorporated trades on the NASDAQ under the ticker symbol "ARAY."

Accuray Incorporated (NASDAQ:ARAY) posted its earnings results on Tuesday, August, 22nd. The company reported ($0.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.05. The business had revenue of $112.09 million for the quarter, compared to analyst estimates of $112 million. Accuray Incorporated had a negative return on equity of 61.62% and a negative net margin of 7.71%. The company's quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.09) earnings per share. View Accuray Incorporated's Earnings History.

Accuray Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Accuray Incorporated.

5 brokers have issued twelve-month price objectives for Accuray Incorporated's shares. Their predictions range from $5.00 to $7.00. On average, they anticipate Accuray Incorporated's share price to reach $6.00 in the next twelve months. View Analyst Ratings for Accuray Incorporated.

Here are some recent quotes from research analysts about Accuray Incorporated stock:

• 1. According to Zacks Investment Research, "Over the past year, Accuray has underperformed the broader industry with respect to price. Accuray reported wider-than-expected loss in the fourth quarter of fiscal 2017, primarily due to lackluster performance in the service revenue segment. The company issued solid fiscal 2018 guidance. Of the recent developments, orders for the latest Radixact System, solid revenue performance in APAC and Japanese regulatory approval for Radixact are key positives in our view. However, unfavorable product mix, declining service revenues, sluggish macro economic conditions and pricing headwinds are major concerns. Notably, China and Europe saw sluggish revenues in the fourth quarter. Accuray’s significant international presence helps broaden its customer base. However, fluctuations in currency exchange rates, particularly with a strong dollar, will continue to adversely impact the company’s backlog and top line." (9/19/2017)
• 2. BTIG Research analysts commented, "Results: In-Line Revenue with Soft Net Orders; Neutral ARAY’s results the past few years seem to reflect a company hampered by its positioning with low market share, missed guidance, delays by the Chinese government and a tough capital structure that is trying to do all that it can to reaccelerate growth. Our concern is that continued single digit growth with lumpy orders and some quarterly revenue misses just doesn’t excite investors and we are not sure what will accelerate growth meaningfully. We applaud new product innovation and focus on consistent results. With guidance reset earlier in the year, ARAY reported in-line rev but the conversion from orders has taken longer than expected with some geographic softness. ARAY is attempting to increase growth through multiple new products such as Radixact, OnRad, Precision Treatment Planning, and iDMS Data Management. We believe this may help but at the end of the day past execution keeps us at Neutral. FY18 guidance calls for revenue of $390M – $400M (2% – 4%) and gross order growth of 5%. Both seem reasonable but also not layups. We will continue to watch for more consistency and stronger growth that would bring investors back into the story." (8/24/2017)
• 3. Aegis analysts commented, "The company has been successful in shifting gears to the smaller vault centers, re-positioning TomoTherapy as a work horse machine. Accuray has moved outside of the niche high-end large academic centers into the broader single- and dual-vault centers, with single- and dual-vault centers now accounting for 50% of new TomoTherapy orders (up from 0% in 2012).He added, "Radixact, the next-generation TomoTherapy platform, was approved for 510k in June (CE Mark in Aug) and brings ARAY up to par with Varian's TrueBeam and Elekta's Axesse machines. Radixact adds higher output dosing along with integrated treatment planning (Precision') and data management (iDMS') systems that will increase the ease and speed of systems, and should have its full launch in time for ARAYs first major replacement cycle. The reliability issues previously associated with TomoTherapy are now behind them, and Tomo is consistantly ranked #1 in overall system performance by ServiceTrak." (2/6/2017)

Some companies that are related to Accuray Incorporated include Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Harvard Bioscience (HBIO), Neovasc (NVCN), IRIDEX Corporation (IRIX), Viveve Medical (VIVE), Edap Tms S.A. (EDAP), Presbia PLC (LENS), Fulgent Genetic (FLGT), Electromed (ELMD), Biolase (BIOL), Invivo Therapeutics Holdings Corp (NVIV), Digirad Corporation (DRAD) and Luna Innovations Incorporated (LUNA).

Accuray Incorporated's management team includes the folowing people:

• Louis J. Lavigne Jr., Independent Chairperson of the Board
• Joshua H. Levine, President, Chief Executive Officer, Director
• Elizabeth H. Davila, Independent Vice Chairperson of the Board
• Kevin Waters, Chief Financial Officer, Senior Vice President
• Alaleh Nouri, Senior Vice President, General Counsel, Corporate Secretary
• Lionel Hadjadjeba, Senior Vice President, Chief Commercial Officer
• Andy Kirkpatrick, Senior Vice President - Global Operations
• Shig Hamamatsu, Vice President, Finance and Chief Accounting Officer, Principal Accounting Officer
• Jack Goldstein Ph.D., Independent Director
• Richard R. Pettingill, Independent Director

Shares of Accuray Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Accuray Incorporated stock can currently be purchased for approximately $4.30.